Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gastroenterology · Gastrinoma

Finding Your Footing After a Gastrinoma Diagnosis

At a Glance

After a gastrinoma diagnosis, treatment focuses first on controlling excess stomach acid with prescribed PPI therapy and then deciding how to manage the tumor. Surgery may be favored for a localized sporadic tumor, while MEN1 cases often require individualized surveillance or surgery.

Being diagnosed with a gastrinoma (pancreatic or duodenal) or Zollinger-Ellison Syndrome (ZES) often brings a mix of relief and frustration. You finally have a name for your symptoms, but you may have spent years being told you simply had “bad reflux” or common ulcers [1]. This journey, often called a diagnostic odyssey, is incredibly common because these tumors are rare and their symptoms mimic everyday digestive issues [2].

Understanding Your Diagnosis

It is helpful to distinguish between the tumor and the syndrome it causes:

  • Gastrinoma: This is the actual tumor, a type of neuroendocrine tumor (NET). It is called a “gastrinoma” because it produces a hormone called gastrin [3]. They can arise in the pancreas, but are very often found in the duodenum.
  • Zollinger-Ellison Syndrome (ZES): This is the name for the condition caused by the tumor. The high levels of gastrin signal your stomach to produce massive amounts of acid, leading to severe ulcers and diarrhea [4].

While the word “tumor” is frightening, well-differentiated gastrinomas are typically slow-growing [5]. However, the real danger in the short term isn’t usually the tumor’s growth, but rather the excess stomach acid it creates in your digestive tract [6].

The Diagnostic Odyssey

If you feel frustrated by how long it took to get here, you are not alone. Research shows that the average time from the start of symptoms to a ZES diagnosis is more than five years [1]. In patients with a genetic condition called MEN1 (Multiple Endocrine Neoplasia type 1), the delay can be even longer—sometimes over seven years [7].

Because standard acid-blocking medications (PPIs like omeprazole) can hide the symptoms and even interfere with diagnostic tests, doctors often overlook the possibility of a rare tumor until standard treatments fail or ulcers keep coming back [6][8].

Recognizing True Emergencies

Living with ZES means dealing with chronic discomfort, but it is vital to know the difference between a “bad day” and a medical emergency.

Common Chronic Symptoms:

  • Frequent watery diarrhea [9].
  • Chronic heartburn or reflux [4].
  • Dull, gnawing abdominal pain that comes and goes [2].

Alarm Symptoms (Seek Prompt Medical Care):
Progressive or unintentional weight loss is an alarm feature that warrants prompt clinical assessment [10].

Red Flags (Seek Immediate Emergency Care):
Untreated or severe ulcers can lead to life-threatening complications like perforation (a hole in the stomach or intestine) or major gastrointestinal bleeding [9][11]. Severe diarrhea can also cause dangerous dehydration.

  1. Vomiting Blood: This may look bright red or like dark “coffee grounds” [9].
  2. Black, Tarry Stools: This often indicates bleeding higher up in the digestive tract (melena) [9].
  3. Sudden, Severe Abdominal Pain: If you experience intense, rigid pain that makes it hard to move, it may signal a perforation [11].
  4. Fainting or Extreme Dizziness: This can be a sign of rapid blood loss or severe dehydration from diarrhea [9].
  5. Severe Dehydration: Inability to keep fluids down, very low urine output, or confusion.

Current Medical Consensus and Uncertainties

The medical community agrees that the primary goal of treatment is twofold: controlling the acid and managing the tumor [12]. High-dose PPI therapy is the “gold standard” for preventing ulcers [6]. Do not stop or change your PPI therapy without a specialist’s plan.

However, there is still active debate regarding surgery, particularly for those with the MEN1 genetic syndrome.

  • What is certain: For “sporadic” gastrinomas (those not linked to MEN1), surgery to remove the tumor is often the preferred path if the tumor hasn’t spread widely [13].
  • What is uncertain: In MEN1 cases, gastrinomas are often tiny and multiple. Because these patients may have many small tumors throughout the duodenum and pancreas, doctors disagree on the “perfect” time for surgery [14][15]. Some experts recommend early surgery to prevent spread, while others prefer “watchful waiting” or active surveillance with medication to avoid the risks of major surgery [16][17].

Your care team will look at your tumor size (often using a 2cm threshold for surgery) and your Ki-67 rate (a measure of how fast cells are dividing) to help decide the best path for you [18][19].

Common questions in this guide

What is the difference between a gastrinoma and Zollinger-Ellison syndrome?
A gastrinoma is the tumor, a neuroendocrine tumor that makes the hormone gastrin. Zollinger-Ellison syndrome is the condition caused by excess gastrin, which drives the stomach to produce too much acid and can lead to ulcers and diarrhea.
Why can a gastrinoma take years to diagnose?
Gastrinomas are rare, and their symptoms can look like common reflux or ulcers. Proton pump inhibitors can reduce symptoms and may interfere with testing, so the possibility of a tumor may not be considered until symptoms persist or ulcers return.
Which symptoms of Zollinger-Ellison syndrome require emergency care?
Vomiting blood, black tarry stools, sudden severe or rigid abdominal pain, fainting, extreme dizziness, or severe dehydration require immediate emergency evaluation. These signs may indicate gastrointestinal bleeding, a perforated ulcer, or dangerous fluid loss.
How is a gastrinoma treated after diagnosis?
Treatment has two goals: control excess stomach acid and manage the tumor. High-dose proton pump inhibitor therapy is commonly used to protect against ulcers; a localized sporadic tumor may be treated with surgery, while MEN1-related disease may require individualized surveillance, medication, or surgery.
What does MEN1 change about gastrinoma surgery?
MEN1-related gastrinomas are often small and multiple in the duodenum and pancreas, so surgery decisions are complex. Doctors may weigh tumor size, a 2-centimeter threshold often used in decision-making, Ki-67 or mitotic rate, evidence of spread, and the risks of surgery against active surveillance.
What do Ki-67 and mitotic rate tell me about my gastrinoma?
Ki-67 and mitotic rate describe how quickly tumor cells are dividing. Along with tumor size and whether the tumor has spread, these results help the care team estimate tumor behavior and discuss surveillance or treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of Zollinger-Ellison Syndrome have you or this center treated in the last five years?
  2. 2.Based on my imaging and labs, is my gastrinoma considered 'sporadic' or related to a genetic syndrome like MEN1?
  3. 3.What is the Ki-67 or mitotic rate of my tumor, and how does that help us understand how fast it might grow?
  4. 4.How will we know if my current dose of acid-blocking medication (PPI) is effectively protecting me from new ulcers?
  5. 5.Is my tumor currently 'localized' to one spot, or are there signs it has spread to lymph nodes or other organs?
  6. 6.If I have MEN1, what are the specific 'triggers' or tumor sizes that would make us move from monitoring to surgery?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

    Rossi RE, Elvevi A, Citterio D, et al.

    World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

    PMID: 34629807
  2. 2

    Delayed Management of Zollinger-Ellison Syndrome in a Noncompliant Patient.

    Klimko A, Plotogea O, Constantinescu A, Constantinescu G

    Cureus 2020; (12(6)):e8471 doi:10.7759/cureus.8471.

    PMID: 32642376
  3. 3

    Sporadic Zollinger-Ellison syndrome in a patient with isolated mesenteric gastrinoma.

    Efared B, Tassiou EIM, Bako ABA, et al.

    International journal of surgery case reports 2024; (116()):109474 doi:10.1016/j.ijscr.2024.109474.

    PMID: 38447521
  4. 4

    All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.

    Chatzipanagiotou O, Schizas D, Vailas M, et al.

    Journal of neuroendocrinology 2023; (35(4)):e13267 doi:10.1111/jne.13267.

    PMID: 37042078
  5. 5

    Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms.

    Gonzalez RS

    Surgical pathology clinics 2020; (13(3)):377-397 doi:10.1016/j.path.2020.04.002.

    PMID: 32773190
  6. 6

    Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.

    Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, et al.

    The American journal of medicine 2017; (130(5)):603-605 doi:10.1016/j.amjmed.2016.11.035.

    PMID: 28011308
  7. 7

    [Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma].

    Guo Y, Chen LH, Liu M, et al.

    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2021; (24(10)):875-882 doi:10.3760/cma.j.cn.441530-20210719-00291.

    PMID: 34674462
  8. 8

    Diagnostic and Treatment Approaches for Refractory Peptic Ulcers.

    Kim HU

    Clinical endoscopy 2015; (48(4)):285-90 doi:10.5946/ce.2015.48.4.285.

    PMID: 26240800
  9. 9

    Severe Recurrent Gastrointestinal Bleeding and Diagnostic Dilemmas in Zollinger-Ellison Syndrome: A Case Report.

    Bragança S, Figueiredo LM, Oliveira AM, et al.

    GE Portuguese journal of gastroenterology 2025; doi:10.1159/000550071.

    PMID: 41623552
  10. 10

    Severe Hypomagnesemia Caused by Proton-Pump Inhibitors in a Patient With an Ostomy.

    Ali K, Ali AA, Jaikaransingh V

    Cureus 2024; (16(3)):e55856 doi:10.7759/cureus.55856.

    PMID: 38590468
  11. 11

    Zollinger-Ellison Syndrome Unmasked during Hiatal Hernia Evaluation: A Case Report.

    Vasireddy R, Gaddipati G, Bilalaga MM, et al.

    Case reports in gastroenterology 2025; (19(1)):219-224 doi:10.1159/000544940.

    PMID: 40607259
  12. 12

    Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study.

    Massironi S, Cavalcoli F, Elvevi A, et al.

    Endocrine 2022; (75(3)):942-948 doi:10.1007/s12020-021-02915-7.

    PMID: 34716542
  13. 13

    The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

    Guarnotta V, Martini C, Davì MV, et al.

    Endocrine 2018; (60(1)):15-27 doi:10.1007/s12020-017-1420-4.

    PMID: 29019150
  14. 14

    How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

    Imamura M, Komoto I, Taki Y

    Surgery today 2023; (53(12)):1325-1334 doi:10.1007/s00595-022-02627-z.

    PMID: 36473964
  15. 15

    European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.

    Hofland J, Falconi M, Christ E, et al.

    Journal of neuroendocrinology 2023; (35(8)):e13318 doi:10.1111/jne.13318.

    PMID: 37578384
  16. 16

    Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

    Gaujoux S, Pattou F, Cadiot G, et al.

    World journal of surgery 2026; (50(5)):1300-1311 doi:10.1002/wjs.70303.

    PMID: 41862416
  17. 17

    Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.

    Giudici F, Cavalli T, Giusti F, et al.

    World journal of surgery 2017; (41(9)):2312-2323 doi:10.1007/s00268-017-4019-2.

    PMID: 28429092
  18. 18

    Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).

    van Beek DJ, Nell S, Pieterman CRC, et al.

    Journal of surgical oncology 2019; (120(6)):966-975 doi:10.1002/jso.25667.

    PMID: 31401809
  19. 19

    Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.

    van Beek DJ, Nell S, Verkooijen HM, et al.

    Surgery 2021; (169(4)):963-973 doi:10.1016/j.surg.2020.09.037.

    PMID: 33220975

This page explains gastrinoma and Zollinger-Ellison syndrome for informational purposes only and does not constitute medical advice. Follow your own specialist’s plan and seek emergency care for bleeding, severe abdominal pain, fainting, or severe dehydration.

Get notified when new evidence is published on pancreatic gastrinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.